These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Diagnostic accuracy of MRI in differentiating hepatocellular adenoma from focal nodular hyperplasia: prospective study of the additional value of gadoxetate disodium. Bieze M; van den Esschert JW; Nio CY; Verheij J; Reitsma JB; Terpstra V; van Gulik TM; Phoa SS AJR Am J Roentgenol; 2012 Jul; 199(1):26-34. PubMed ID: 22733890 [TBL] [Abstract][Full Text] [Related]
6. [Gd-EOB-DTPA-enhanced magnetic resonance imaging: differentiation between focal nodular hyperplasia and hepatocellular adenoma]. Portilha MA; Pedro MT; Ruivo C; Semedo LC; Marques C; Alves FC Acta Med Port; 2011 Dec; 24 Suppl 2():531-8. PubMed ID: 22849944 [TBL] [Abstract][Full Text] [Related]
7. Value of Texture Analysis on Gadoxetic Acid-Enhanced MRI for Differentiating Hepatocellular Adenoma From Focal Nodular Hyperplasia. Cannella R; Rangaswamy B; Minervini MI; Borhani AA; Tsung A; Furlan A AJR Am J Roentgenol; 2019 Mar; 212(3):538-546. PubMed ID: 30557050 [TBL] [Abstract][Full Text] [Related]
8. Differentiation Between Hepatocellular Carcinoma Showing Hyperintensity on the Hepatobiliary Phase of Gadoxetic Acid-Enhanced MRI and Focal Nodular Hyperplasia by CT and MRI. Kitao A; Matsui O; Yoneda N; Kita R; Kozaka K; Kobayashi S; Gabata T AJR Am J Roentgenol; 2018 Aug; 211(2):347-357. PubMed ID: 29708786 [TBL] [Abstract][Full Text] [Related]
9. Differentiation of focal nodular hyperplasia and hepatocellular adenoma using qualitative and quantitative imaging features and classification and regression tree analysis. Alamri TM; Cerny M; Al Shaikh M; Billiard JS; Olivié D; Chagnon M; Tang A Abdom Radiol (NY); 2023 Mar; 48(3):874-885. PubMed ID: 36528729 [TBL] [Abstract][Full Text] [Related]
10. Diagnostic value of morphological enhancement patterns in the hepatobiliary phase of gadoxetic acid-enhanced MRI to distinguish focal nodular hyperplasia from hepatocellular adenoma. Bilreiro C; Soler JC; Ayuso JR; Caseiro-Alves F; Ayuso C Radiol Med; 2021 Nov; 126(11):1379-1387. PubMed ID: 34287759 [TBL] [Abstract][Full Text] [Related]
11. OATPB1/B3 and MRP3 expression in hepatocellular adenoma predicts Gd-EOB-DTPA uptake and correlates with risk of malignancy. Sciarra A; Schmidt S; Pellegrinelli A; Maggioni M; Dondossola D; Pasquier J; Cigala C; Tosi D; Halkic N; Bulfamante G; Viale G; Bosari S; Balabaud C; Bioulac-Sage P; Sempoux C Liver Int; 2019 Jan; 39(1):158-167. PubMed ID: 30218633 [TBL] [Abstract][Full Text] [Related]
12. Diagnostic Value of Gadoxetic Acid-Enhanced MR Imaging to Distinguish HCA and Its Subtype from FNH: A Systematic Review. Guo Y; Li W; Cai W; Zhang Y; Fang Y; Hong G Int J Med Sci; 2017; 14(7):668-674. PubMed ID: 28824299 [No Abstract] [Full Text] [Related]
13. Differentiating focal nodular hyperplasia from hepatocellular adenoma: Is hepatobiliary phase MRI (HBP-MRI) using linear gadolinium chelates always useful? Roux M; Pigneur F; Baranes L; Calderaro J; Chiaradia M; Decaens T; Kastahian S; Charles-Nelson A; Tselikas L; Costentin C; Laurent A; Azoulay D; Mallat A; Rahmouni A; Luciani A Abdom Radiol (NY); 2018 Jul; 43(7):1670-1681. PubMed ID: 29110059 [TBL] [Abstract][Full Text] [Related]
14. Enhancement of the liver and pancreas in the hepatic arterial dominant phase: comparison of hepatocyte-specific MRI contrast agents, gadoxetic acid and gadobenate dimeglumine, on 3 and 1.5 Tesla MRI in the same patient. Kim HJ; Kim BS; Kim MJ; Kim SH; de Campos RO; Hernandes M; Semelka RC J Magn Reson Imaging; 2013 Apr; 37(4):903-8. PubMed ID: 23065959 [TBL] [Abstract][Full Text] [Related]
15. Gadoxetic acid enhanced MRI for differentiation of FNH and HCA: a single centre experience. Grieser C; Steffen IG; Kramme IB; Bläker H; Kilic E; Perez Fernandez CM; Seehofer D; Schott E; Hamm B; Denecke T Eur Radiol; 2014 Jun; 24(6):1339-48. PubMed ID: 24658870 [TBL] [Abstract][Full Text] [Related]
16. Characteristics and distinguishing features of hepatocellular adenoma and focal nodular hyperplasia on gadoxetate disodium-enhanced MRI. Purysko AS; Remer EM; Coppa CP; Obuchowski NA; Schneider E; Veniero JC AJR Am J Roentgenol; 2012 Jan; 198(1):115-23. PubMed ID: 22194486 [TBL] [Abstract][Full Text] [Related]
17. Differentiation of hepatic hyperintense lesions seen on gadoxetic acid-enhanced hepatobiliary phase MRI. Suh YJ; Kim MJ; Choi JY; Park YN; Park MS; Kim KW AJR Am J Roentgenol; 2011 Jul; 197(1):W44-52. PubMed ID: 21700994 [TBL] [Abstract][Full Text] [Related]
18. The diagnostic value of Gd-EOB-DTPA-MRI for the diagnosis of focal nodular hyperplasia: a systematic review and meta-analysis. Suh CH; Kim KW; Kim GY; Shin YM; Kim PN; Park SH Eur Radiol; 2015 Apr; 25(4):950-60. PubMed ID: 25537979 [TBL] [Abstract][Full Text] [Related]
19. HBP-enhancing hepatocellular adenomas and how to discriminate them from FNH in Gd-EOB MRI. Auer TA; Walter-Rittel T; Geisel D; Schöning W; Schmelzle M; Müller T; Sinn B; Denecke T; Hamm B; Fehrenbach U BMC Med Imaging; 2021 Feb; 21(1):28. PubMed ID: 33588783 [TBL] [Abstract][Full Text] [Related]
20. Intrapatient Comparison of the Hepatobiliary Phase of Gd-BOPTA and Gd-EOB-DTPA in the Differentiation of Hepatocellular Adenoma From Focal Nodular Hyperplasia. Vanhooymissen IJSML; Thomeer MG; Braun LMM; Gest B; van Koeverden S; Willemssen FE; Hunink M; De Man RA; Ijzermans JN; Dwarkasing RS J Magn Reson Imaging; 2019 Mar; 49(3):700-710. PubMed ID: 30252977 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]